Supplemental Table 2. Absolute value and percent change for concentration of TG in 20 subclasses.
|
A. Baseline | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Measured value, mg/dL | ||||||||||||||||||||
| Placebo | 5.35 ± 10.46 | 4.53 ± 5.17 | 13.64 ± 10.89 | 25.50 ± 16.28 | 29.48 ± 14.35 | 14.85 ± 6.06 | 6.61 ± 2.12 | 9.75 ± 2.54 | 9.61 ± 2.41 | 4.42 ± 1.27 | 1.42 ± 0.45 | 0.43 ± 0.28 | 0.34 ± 0.18 | 0.25 ± 0.15 | 0.69 ± 0.46 | 3.21 ± 1.95 | 5.04 ± 2.14 | 3.26 ± 1.28 | 0.81 ± 0.42 | 1.14 ± 0.27 |
| Evolocumab | 4.98 ± 8.29 | 4.43 ± 5.61 | 13.56 ± 12.82 | 25.95 ± 19.27 | 30.38 ± 16.36 | 15.41 ± 6.64 | 6.59 ± 2.09 | 9.75 ± 2.66 | 9.66 ± 2.65 | 4.44 ± 1.39 | 1.41 ± 0.48 | 0.44 ± 0.25 | 0.35 ± 0.16 | 0.25 ± 0.15 | 0.75 ± 0.60 | 3.30 ± 2.22 | 5.05 ± 2.20 | 3.32 ± 1.38 | 0.84 ± 0.45 | 1.15 ± 0.25 |
|
B. Week 12 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Measured value, mg/dL | ||||||||||||||||||||
| Placebo | 4.75 ± 5.99 | 4.36 ± 4.65 | 13.36 ± 11.76 | 25.32 ± 18.29 | 29.60 ± 15.72 | 15.25 ± 6.42 | 6.68 ± 2.02 | 9.77 ± 2.41 | 9.63 ± 2.45 | 4.46 ± 1.36 | 1.42 ± 0.48 | 0.43 ± 0.22 | 0.34 ± 0.14 | 0.25 ± 0.12 | 0.69 ± 0.40 | 3.21 ± 1.82 | 4.94 ± 1.87 | 3.22 ± 1.19 | 0.81 ± 0.39 | 1.13 ± 0.20 |
| Evolocumab | 4.19 ± 9.12 | 3.41 ± 5.14 | 10.09 ± 10.83 | 19.02 ± 15.15 | 21.59 ± 12.98 | 11.95 ± 5.52 | 4.98 ± 1.51 | 6.86 ± 1.75 | 6.23 ± 1.70 | 2.91 ± 0.92 | 0.93 ± 0.33 | 0.34 ± 0.23 | 0.27 ± 0.15 | 0.21 ± 0.16 | 0.76 ± 0.62 | 3.68 ± 2.51 | 4.91 ± 2.44 | 2.96 ± 1.34 | 0.73 ± 0.41 | 1.09 ± 0.25 |
| Change from baseline, % | ||||||||||||||||||||
| Placebo | −5.98 (−44.44, 71.43) | −9.83 (−44.50, 58.17) | −10.97 (−38.34, 37.45) | −5.10 (−33.18, 36.20) | 0.53 (−21.55, 22.80) | 3.77 (−15.04, 25.40) | 1.84 (−12.15, 16.48) | 0.89 (−9.44, 12.43) | 1.30 (−7.83, 7.62) | 1.16 (−8.93, 10.20) | 0.74 (−10.81, 11.76) | 0.00 (−18.00, 22.22) | 0.00 (−11.54, 17.02) | 3.03 (−17.24, 25.00) | 6.19 (−20.00, 31.48) | 5.08 (−17.21, 21.57) | 0.67 (−15.14, 18.21) | −0.60 (−15.95, 17.43) | 1.33 (−20.00, 26.32) | 0.00 (−6.72, 8.41) |
| Evolocumab | −24.76 (−64.03, 55.23) | −29.86 (−60.53, 36.29) | −30.90 (−57.02, 9.54) | −27.75 (−49.10, 3.12) | −31.39 (−44.96, −12.79) | −20.99 (−39.05, −5.20) | −25.53 (−34.10, −9.85) | −29.88 (−37.96, −19.29) | −35.38 (−42.98, −26.23) | −34.13 (−43.22, −23.86) | −33.57 (−42.15, −22.73) | −20.51 (−38.10, −5.26) | −20.59 (−35.29, −7.41) | −16.67 (−37.50, 5.56) | 1.96 (−21.54, 25.00) | 11.44 (−8.65, 39.56) | −3.83 (−21.81, 17.34) | −10.33 (−29.73, 7.92) | −11.48 (−30.77, 12.36) | −3.19 (−10.95, 3.85) |
|
C. Mean of weeks 10 and 12 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub class 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Measured value, mg/dL | ||||||||||||||||||||
| Placebo | 4.88 ± 5.22 | 4.39 ± 3.99 | 13.17 ± 9.94 | 24.84 ± 15.34 | 29.27 ± 13.49 | 15.16 ± 5.80 | 6.60 ± 1.91 | 9.63 ± 2.37 | 9.45 ± 2.38 | 4.38 ± 1.28 | 1.41 ± 0.44 | 0.43 ± 0.20 | 0.34 ± 0.13 | 0.25 ± 0.11 | 0.69 ± 0.38 | 3.17 ± 1.75 | 4.87 ± 1.77 | 3.19 ± 1.09 | 0.80 ± 0.35 | 1.13 ± 0.19 |
| Evolocumab | 4.26 ± 8.10 | 3.34 ± 4.38 | 9.66 ± 9.04 | 18.05 ± 12.67 | 20.58 ± 11.15 | 11.59 ± 4.89 | 4.88 ± 1.43 | 6.67 ± 1.64 | 5.95 ± 1.52 | 2.76 ± 0.80 | 0.89 ± 0.28 | 0.34 ± 0.21 | 0.27 ± 0.13 | 0.21 ± 0.14 | 0.76 ± 0.56 | 3.66 ± 2.28 | 4.90 ± 2.10 | 2.94 ± 1.18 | 0.72 ± 0.37 | 1.08 ± 0.23 |
| Change from baseline, % | ||||||||||||||||||||
| Placebo | 10.29 (−38.51, 102.94) | 0.39 (−30.95, 69.89) | −4.95 (−32.80, 39.36) | −4.37 (−27.27, 32.13) | −1.00 (−18.78, 23.26) | 1.52 (−12.33, 20.60) | 0.32 (−11.02, 14.42) | −0.29 (−10.18, 8.97) | −1.05 (−9.36, 5.57) | −0.79 (−9.83, 8.07) | −0.84 (−10.00, 8.82) | 2.44 (−10.83, 21.67) | 1.85 (−8.93, 15.63) | 2.63 (−14.71, 27.50) | 5.41 (−15.07, 28.70) | 1.66 (−12.93, 21.29) | −1.12 (−14.31, 16.71) | −1.35 (−16.72, 16.80) | 2.83 (−17.91, 23.44) | 0.40 (−7.02, 7.43) |
| Evolocumab | −6.87 (−52.78, 72.73) | −19.64 (−50.22, 39.73) | −26.58 (−53.56, 10.25) | −28.66 (−48.38, −2.66) | −32.83 (−47.32, −15.53) | −24.32 (−38.62, −10.35) | −24.02 (−36.66, −14.52) | −30.78 (−38.42, −23.25) | −38.12 (−43.78, −29.16) | −36.88 (−44.61, −27.72) | −34.95 (−43.50, −26.50) | −21.43 (−35.71, −5.56) | −20.59 (−34.48, −8.70) | −14.71 (−34.38, 3.33) | 4.23 (−16.67, 30.65) | 14.21 (−6.91, 43.40) | −2.63 (−19.43, 20.54) | −10.28 (−26.46, 8.12) | −11.43 (−28.95, 12.50) | −3.40 (−11.56, 3.76) |
Data are expressed as mean ± SD or median (interquartile range). Abbreviation: TG, triglyceride.